Skip to content

Merck & Co

US · MRK #43 by market cap Listed 1970
143.63 -2.32 -1.59%
Live - 5344 symbols - heartbeat 21s ago · 2026-10-20 08:29

Recent news

  • Morgan Stanley Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $177
    Market Newswire · 2026/10/7
  • Rating change
    Morgan Stanley Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $179
    Market Newswire · 2026/9/21
  • Company notice
    MRK Holdings: Marco Co., Ltd. has obtained certification as a "Gender‑Friendly Plus" business operator in Osaka Prefecture.
    JPX · 2026/9/11
  • Rating change
    BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $166
    Market Newswire · 2026/9/23
  • BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $170
    Market Newswire · 2026/10/8
  • UBS Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $175
    Market Newswire · 2026/10/9
  • Company notice
    MRK Holdings: Notice: "A Musical Hour for Adults," hosted by MISEL Co., Ltd.
    JPX · 2026/7/10
  • Rating change
    TD Cowen Maintains Merck & Co(MRK.US) With Hold Rating, Raises Target Price to $155
    Market Newswire · 2026/9/23
  • Company notice
    MRK Holdings: Notice of the "Live Entertainment Show ~You & I~" hosted by MISEL Co., Ltd.
    JPX · 2026/7/10
  • Cantor Fitzgerald Maintains Merck & Co(MRK.US) With Hold Rating, Raises Target Price to $145
    Market Newswire · 2026/10/8
  • Rating change
    J.P. Morgan Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $165
    Market Newswire · 2026/10/5
  • Rating change
    Scotiabank Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $180
    Market Newswire · 2026/9/29
  • BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $163
    Market Newswire · 2026/10/9
  • Company notice
    MRK Holdings: Notice of Corporate Logo Change for MRK Holdings Co., Ltd.
    JPX · 2026/10/1
  • Rating change
    Scotiabank Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $155
    Market Newswire · 2026/9/23
  • Rating change
    RBC Capital Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $150
    Market Newswire · 2026/10/1
  • Company notice
    MRK Holdings: Matters concerning controlling shareholders, etc.
    JPX · 2026/6/15
  • Rating change
    Goldman Sachs Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $160
    Market Newswire · 2026/10/1
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Merck & Company (MRK)
    TipRanks · 2026/9/25
  • Rating change
    DBS Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $180
    Market Newswire · 2026/9/12
  • Rating change
    Leerink Partners Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $161
    Market Newswire · 2026/9/10
  • Rating change
    Barclays Downgrades Merck & Co(MRK.US) to Hold Rating, Raises Target Price to $174.46
    Market Newswire · 2026/9/8
  • Rating change
    Guggenheim Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $170
    Market Newswire · 2026/9/8
  • UBS Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $175
    Market Newswire · 2026/9/24
  • BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $170
    Market Newswire · 2026/9/25

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-20 08:29:32 · For reference only, not investment advice and not tailored to your situation.

Merck & Co discussion 1 comments

  1. the keytruda patent cliff is a few years out but the market’s already discounting it hard. pipeline needs to deliver or this stays cheap for a while, that’s the whole debate in one sentence.

Add a comment